ArticleOncoimmunology

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Christian Klein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.